Boston Scientific Co
BSX
Real-time BATS EXCHANGE - 06/20 05:20:45 pm
32.325USD
+1.32%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales9 0489 839
EBITDA2 5472 843
Operating profit (EBIT)2 2682 507
Pre-Tax Profit (EBT)--
Net income1041 347
EPS ( $ )0,080,97
Dividend per Share ( $ )--
Yield--
Announcement Date02/01/2018
11:30am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt5 4284 828
Finance--
Operating income (EBITDA)2 5472 843
Leverage
(Debt/EBITDA)
2,13x1,70x
Capital Expenditure319325
Book Value Per Share (BVPS)5,10 $6,24 $
Cash Flow per Share1,02 $1,45 $
Announcement Date02/01/2018
11:30am
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 44 554 M$ -
Entreprise Value (EV) 49 382 M$ 47 750 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 33,0x 27,1x
Capitalization / Revenue 4,53x 4,25x
EV / Revenue 5,02x 4,55x
EV / EBITDA 17,4x 15,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 5,12x 4,66x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 25,5% 27,0%
operating Leverage (Delta EBIT / Delta Sales) 1,20x 1,96x
Net Margin (Net Profit / Revenue) 13,7% 15,9%
ROA (Net Profit / Asset) 8,45% 9,65%
ROE (Net Profit / Equities) 24,0% 25,1%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   3,30% 3,41%
Cash Flow / Sales 20,3% 23,0%
Capital Intensity (Assets / Sales) 1,62x 1,64x
Financial Leverage (Net Debt / EBITDA) 1,70x 1,02x
Price Earning Ratio
BNA & Dividende